Rajni Kannan, BS, MS, RN, ANP-BC, Perlmutter Cancer Center at NYU Langone, gives an overview of immune related adverse events (IRAEs).
Rajni Kannan, BS, MS, RN, ANP-BC, Perlmutter Cancer Center at NYU Langone, gives an overview of immune related adverse events (IRAEs).
Kannan says the adverse events seen in patients taking immunotherapy agents are classified differently than other adverse events. These new immunotherapy agents are activating T cells that not only go after the cancer, but also to work on the healthy tissues.
The most common side effects seen with immunotherapies are diarrhea and rash but patients may also experience pseudo hepatitis, endocrinopathies, and eye toxicities.
PVd Confers a Small OS Benefit to Patients With Relapsed/Refractory Multiple Myeloma
Neoadjuvant Durvalumab Combination Misses Mark in EGFR+ NSCLC
Durvalumab Garners Similar OS, Albeit Varied PFS, Outcomes in EGFR+ and EGFR-Wildtype NSCLC Subgroups
Quizartinib Extends Overall Survival Across Multiple Subgroups in FLT3-ITD+ AML
2 Clarke Drive
Cranbury, NJ 08512